Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2010

Open Access 01-12-2010 | Research

Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound

Authors: Alireza Esteghamati, Arsia Jamali, Omid Khalilzadeh, Sina Noshad, Mohammad Khalili, Ali Zandieh, Afsaneh Morteza, Manouchehr Nakhjavani

Published in: Diabetology & Metabolic Syndrome | Issue 1/2010

Login to get access

Abstract

Background

Despite ongoing findings on the relationship between elevated levels of alanine and aspartate aminotransferases (ALT and AST) and metabolic syndrome (MetS), this association in diabetic patients without a known cause for liver enzymes elevation other than diabetes, per se, remains unclear. In this study, we aimed to assess the relationship between circulating liver enzymes and MetS in a relatively large sample of patients with diabetes.

Methods

A total of 670 diabetic patients, without known causes of hepatocellular injury, were enrolled. Patients with ultrasonographic signs of fatty liver disease were not included. Fasting blood samples were obtained and biochemical characteristics were measured. MetS was defined according to the international diabetes federation criteria.

Results

Serum ALT and AST were significantly higher in patients with MetS (p < 0.001). High waist circumference and low HDL-cholesterol were significantly associated with elevated ALT (OR = 2.56 and 2.0, respectively) and AST (OR = 2.23 and 2.21, respectively). ALT and AST were significantly associated with MetS (OR = 2.17 and 2.31, respectively). These associations remained significant after multiple adjustments for age, sex, BMI, diabetes duration, HbA1c and medications. There was a significant (p < 0.01) positive association between the number of the MetS features and the level of ALT or AST.

Conclusion

In diabetic patients without ultrasonographic evidence of fatty liver, elevated aminotransferases are independently associated with MetS. Despite negative ultrasound results in diabetic patients with MetS, the serum level of liver aminotransferases may be elevated and should be more thoroughly monitored.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lopez-Bermejo A, Botas P, Funahashi T, Delgado E, Kihara S, Ricart W, Fernandez-Real JM: Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf). 2004, 60 (2): 256-263. 10.1046/j.1365-2265.2004.01977.x.CrossRef Lopez-Bermejo A, Botas P, Funahashi T, Delgado E, Kihara S, Ricart W, Fernandez-Real JM: Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf). 2004, 60 (2): 256-263. 10.1046/j.1365-2265.2004.01977.x.CrossRef
2.
go back to reference Kew MC: Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet. 2000, 355 (9204): 591-592. 10.1016/S0140-6736(99)00219-6.CrossRefPubMed Kew MC: Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet. 2000, 355 (9204): 591-592. 10.1016/S0140-6736(99)00219-6.CrossRefPubMed
3.
go back to reference Keil E: Determination of enzyme activities in serum for the detection of xenobiotic effects on the liver. Exp Pathol. 1990, 39 (3-4): 157-164.CrossRefPubMed Keil E: Determination of enzyme activities in serum for the detection of xenobiotic effects on the liver. Exp Pathol. 1990, 39 (3-4): 157-164.CrossRefPubMed
4.
go back to reference Herrera JL: Abnormal liver enzyme levels. The spectrum of causes. Postgrad Med. 1993, 93 (2): 113-116.PubMed Herrera JL: Abnormal liver enzyme levels. The spectrum of causes. Postgrad Med. 1993, 93 (2): 113-116.PubMed
5.
go back to reference Sherman KE: Alanine aminotransferase in clinical practice. A review. Arch Intern Med. 1991, 151 (2): 260-265. 10.1001/archinte.151.2.260.CrossRefPubMed Sherman KE: Alanine aminotransferase in clinical practice. A review. Arch Intern Med. 1991, 151 (2): 260-265. 10.1001/archinte.151.2.260.CrossRefPubMed
6.
go back to reference Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA: High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002, 51 (6): 1889-1895. 10.2337/diabetes.51.6.1889.CrossRefPubMed Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA: High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002, 51 (6): 1889-1895. 10.2337/diabetes.51.6.1889.CrossRefPubMed
7.
go back to reference Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes. 2004, 53 (11): 2855-2860. 10.2337/diabetes.53.11.2855.CrossRefPubMed Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes. 2004, 53 (11): 2855-2860. 10.2337/diabetes.53.11.2855.CrossRefPubMed
8.
go back to reference Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Kempf J, Zinman B, Haffner SM: Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004, 53 (10): 2623-2632. 10.2337/diabetes.53.10.2623.CrossRefPubMed Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Kempf J, Zinman B, Haffner SM: Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004, 53 (10): 2623-2632. 10.2337/diabetes.53.10.2623.CrossRefPubMed
9.
go back to reference Nakanishi N, Suzuki K, Tatara K: Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004, 27 (6): 1427-1432. 10.2337/diacare.27.6.1427.CrossRefPubMed Nakanishi N, Suzuki K, Tatara K: Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004, 27 (6): 1427-1432. 10.2337/diacare.27.6.1427.CrossRefPubMed
10.
go back to reference Clark JM, Diehl AM: Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003, 289 (22): 3000-3004. 10.1001/jama.289.22.3000.CrossRefPubMed Clark JM, Diehl AM: Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003, 289 (22): 3000-3004. 10.1001/jama.289.22.3000.CrossRefPubMed
11.
go back to reference Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003, 98 (5): 960-967. 10.1111/j.1572-0241.2003.07486.x.CrossRefPubMed Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003, 98 (5): 960-967. 10.1111/j.1572-0241.2003.07486.x.CrossRefPubMed
12.
go back to reference Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, Cassader M: Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care. 2008, 31 (3): 562-568. 10.2337/dc07-1526.CrossRefPubMed Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, Cassader M: Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care. 2008, 31 (3): 562-568. 10.2337/dc07-1526.CrossRefPubMed
13.
go back to reference Stein LL, Dong MH, Loomba R: Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther. 2009, 26 (10): 893-907. 10.1007/s12325-009-0072-z.CrossRefPubMed Stein LL, Dong MH, Loomba R: Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther. 2009, 26 (10): 893-907. 10.1007/s12325-009-0072-z.CrossRefPubMed
14.
go back to reference Edmison J, McCullough AJ: Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis. 2007, 11 (1): 75-104. 10.1016/j.cld.2007.02.011. ixCrossRefPubMed Edmison J, McCullough AJ: Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis. 2007, 11 (1): 75-104. 10.1016/j.cld.2007.02.011. ixCrossRefPubMed
15.
go back to reference Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 2002, 346 (16): 1221-1231. 10.1056/NEJMra011775.CrossRefPubMed Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 2002, 346 (16): 1221-1231. 10.1056/NEJMra011775.CrossRefPubMed
16.
go back to reference Torres DM, Harrison SA: Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008, 134 (6): 1682-1698. 10.1053/j.gastro.2008.02.077.CrossRefPubMed Torres DM, Harrison SA: Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008, 134 (6): 1682-1698. 10.1053/j.gastro.2008.02.077.CrossRefPubMed
17.
go back to reference Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008, 31 (Suppl 1(1)): S55-60. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008, 31 (Suppl 1(1)): S55-60.
18.
go back to reference Esteghamati A, Abbasi M, Rashidi A, Meysamie A, Khalilzadeh O, Haghazali M, Asgari F, Nakhjavani M: Optimal waist circumference cut-offs for the diagnosis of metabolic syndrome in Iranian adults: results of the third national survey of risk factors of non-communicable diseases (SuRFNCD-2007). Diabet Med. 2009, 26 (7): 745-746. 10.1111/j.1464-5491.2009.02756.x.CrossRefPubMed Esteghamati A, Abbasi M, Rashidi A, Meysamie A, Khalilzadeh O, Haghazali M, Asgari F, Nakhjavani M: Optimal waist circumference cut-offs for the diagnosis of metabolic syndrome in Iranian adults: results of the third national survey of risk factors of non-communicable diseases (SuRFNCD-2007). Diabet Med. 2009, 26 (7): 745-746. 10.1111/j.1464-5491.2009.02756.x.CrossRefPubMed
19.
go back to reference Alberti KG, Zimmet P, Shaw J: Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006, 23 (5): 469-480. 10.1111/j.1464-5491.2006.01858.x.CrossRefPubMed Alberti KG, Zimmet P, Shaw J: Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006, 23 (5): 469-480. 10.1111/j.1464-5491.2006.01858.x.CrossRefPubMed
20.
go back to reference Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130 (6): 461-470.CrossRefPubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130 (6): 461-470.CrossRefPubMed
21.
go back to reference Lentjes EG, Harff GA, Backer ET: Evaluation of the Hitachi 704 automatic analyzer. Clin Chem. 1987, 33 (11): 2089-2092.PubMed Lentjes EG, Harff GA, Backer ET: Evaluation of the Hitachi 704 automatic analyzer. Clin Chem. 1987, 33 (11): 2089-2092.PubMed
22.
go back to reference Hickman IJ, Whitehead JP, Prins JB, Macdonald GA: Raised alanine transaminase and decreased adiponectin are features of the metabolic syndrome in patients with type 2 diabetes. Diabetes Obes Metab. 2007, 9 (3): 438-440. 10.1111/j.1463-1326.2006.00604.x.CrossRefPubMed Hickman IJ, Whitehead JP, Prins JB, Macdonald GA: Raised alanine transaminase and decreased adiponectin are features of the metabolic syndrome in patients with type 2 diabetes. Diabetes Obes Metab. 2007, 9 (3): 438-440. 10.1111/j.1463-1326.2006.00604.x.CrossRefPubMed
23.
go back to reference Forlani G, Di Bonito P, Mannucci E, Capaldo B, Genovese S, Orrasch M, Scaldaferri L, Di Bartolo P, Melandri P, Dei Cas A: Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest. 2008, 31 (2): 146-152.CrossRefPubMed Forlani G, Di Bonito P, Mannucci E, Capaldo B, Genovese S, Orrasch M, Scaldaferri L, Di Bartolo P, Melandri P, Dei Cas A: Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest. 2008, 31 (2): 146-152.CrossRefPubMed
24.
go back to reference Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003, 37 (6): 1286-1292. 10.1053/jhep.2003.50229.CrossRefPubMed Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003, 37 (6): 1286-1292. 10.1053/jhep.2003.50229.CrossRefPubMed
25.
go back to reference Day CP: Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002, 16 (5): 663-678. 10.1053/bega.2002.0333.CrossRefPubMed Day CP: Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002, 16 (5): 663-678. 10.1053/bega.2002.0333.CrossRefPubMed
26.
go back to reference Tohidi M, Harati H, Hadaegh F, Mehrabi Y, Azizi F: Association of liver enzymes with incident type 2 diabetes: A nested case control study in an Iranian population. BMC Endocr Disord. 2008, 8 (5): 5-10.1186/1472-6823-8-5.PubMedCentralCrossRefPubMed Tohidi M, Harati H, Hadaegh F, Mehrabi Y, Azizi F: Association of liver enzymes with incident type 2 diabetes: A nested case control study in an Iranian population. BMC Endocr Disord. 2008, 8 (5): 5-10.1186/1472-6823-8-5.PubMedCentralCrossRefPubMed
27.
go back to reference Unger RH: Lipotoxic diseases. Annu Rev Med. 2002, 53: 319-336. 10.1146/annurev.med.53.082901.104057.CrossRefPubMed Unger RH: Lipotoxic diseases. Annu Rev Med. 2002, 53: 319-336. 10.1146/annurev.med.53.082901.104057.CrossRefPubMed
28.
go back to reference Day CP, Saksena S: Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol. 2002, 17 (Suppl 3(3)): S377-384. 10.1046/j.1440-1746.17.s3.31.x.CrossRefPubMed Day CP, Saksena S: Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol. 2002, 17 (Suppl 3(3)): S377-384. 10.1046/j.1440-1746.17.s3.31.x.CrossRefPubMed
29.
go back to reference Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001, 50 (8): 1844-1850. 10.2337/diabetes.50.8.1844.CrossRefPubMed Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001, 50 (8): 1844-1850. 10.2337/diabetes.50.8.1844.CrossRefPubMed
31.
go back to reference Crowley H, Lewis WD, Gordon F, Jenkins R, Khettry U: Steatosis in donor and transplant liver biopsies. Hum Pathol. 2000, 31 (10): 1209-1213. 10.1053/hupa.2000.18473.CrossRefPubMed Crowley H, Lewis WD, Gordon F, Jenkins R, Khettry U: Steatosis in donor and transplant liver biopsies. Hum Pathol. 2000, 31 (10): 1209-1213. 10.1053/hupa.2000.18473.CrossRefPubMed
32.
go back to reference Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD: Non-invasive means of measuring hepatic fat content. World J Gastroenterol. 2008, 14 (22): 3476-3483. 10.3748/wjg.14.3476.PubMedCentralCrossRefPubMed Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD: Non-invasive means of measuring hepatic fat content. World J Gastroenterol. 2008, 14 (22): 3476-3483. 10.3748/wjg.14.3476.PubMedCentralCrossRefPubMed
33.
go back to reference Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE, Horii SC: Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol. 1998, 171 (3): 659-664.CrossRefPubMed Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE, Horii SC: Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol. 1998, 171 (3): 659-664.CrossRefPubMed
34.
go back to reference Johnston RJ, Stamm ER, Lewin JM, Hendrick RE, Archer PG: Diagnosis of fatty infiltration of the liver on contrast enhanced CT: limitations of liver-minus-spleen attenuation difference measurements. Abdom Imaging. 1998, 23 (4): 409-415. 10.1007/s002619900370.CrossRefPubMed Johnston RJ, Stamm ER, Lewin JM, Hendrick RE, Archer PG: Diagnosis of fatty infiltration of the liver on contrast enhanced CT: limitations of liver-minus-spleen attenuation difference measurements. Abdom Imaging. 1998, 23 (4): 409-415. 10.1007/s002619900370.CrossRefPubMed
35.
go back to reference Ma J, Son JB, Zhou Y, Le-Petross H, Choi H: Fast spin-echo triple-echo dixon (fTED) technique for efficient T2-weighted water and fat imaging. Magn Reson Med. 2007, 58 (1): 103-109. 10.1002/mrm.21268.CrossRefPubMed Ma J, Son JB, Zhou Y, Le-Petross H, Choi H: Fast spin-echo triple-echo dixon (fTED) technique for efficient T2-weighted water and fat imaging. Magn Reson Med. 2007, 58 (1): 103-109. 10.1002/mrm.21268.CrossRefPubMed
36.
go back to reference Qayyum A, Goh JS, Kakar S, Yeh BM, Merriman RB, Coakley FV: Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques--initial experience. Radiology. 2005, 237 (2): 507-511. 10.1148/radiol.2372040539.CrossRefPubMed Qayyum A, Goh JS, Kakar S, Yeh BM, Merriman RB, Coakley FV: Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques--initial experience. Radiology. 2005, 237 (2): 507-511. 10.1148/radiol.2372040539.CrossRefPubMed
37.
go back to reference Pilleul F, Chave G, Dumortier J, Scoazec JY, Valette PJ: Fatty infiltration of the liver. Detection and grading using dual T1 gradient echo sequences on clinical MR system. Gastroenterol Clin Biol. 2005, 29 (11): 1143-1147. 10.1016/S0399-8320(05)82179-7.CrossRefPubMed Pilleul F, Chave G, Dumortier J, Scoazec JY, Valette PJ: Fatty infiltration of the liver. Detection and grading using dual T1 gradient echo sequences on clinical MR system. Gastroenterol Clin Biol. 2005, 29 (11): 1143-1147. 10.1016/S0399-8320(05)82179-7.CrossRefPubMed
38.
go back to reference Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, Suh DJ, Kim KM, Bae MH, Lee JY: Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 52 (4): 579-585. 10.1016/j.jhep.2010.01.008. Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, Suh DJ, Kim KM, Bae MH, Lee JY: Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 52 (4): 579-585. 10.1016/j.jhep.2010.01.008.
39.
go back to reference Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Croce LS, Grigolato P, Paoletti S, de Bernard B: Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging. 1995, 5 (3): 281-285. 10.1002/jmri.1880050311.CrossRefPubMed Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Croce LS, Grigolato P, Paoletti S, de Bernard B: Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging. 1995, 5 (3): 281-285. 10.1002/jmri.1880050311.CrossRefPubMed
40.
go back to reference Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O: Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging. 1994, 12 (3): 487-495. 10.1016/0730-725X(94)92543-7.CrossRefPubMed Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O: Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging. 1994, 12 (3): 487-495. 10.1016/0730-725X(94)92543-7.CrossRefPubMed
Metadata
Title
Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound
Authors
Alireza Esteghamati
Arsia Jamali
Omid Khalilzadeh
Sina Noshad
Mohammad Khalili
Ali Zandieh
Afsaneh Morteza
Manouchehr Nakhjavani
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2010
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-2-65

Other articles of this Issue 1/2010

Diabetology & Metabolic Syndrome 1/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.